| Literature DB >> 32730238 |
Mark W Tenforde, Sara S Kim, Christopher J Lindsell, Erica Billig Rose, Nathan I Shapiro, D Clark Files, Kevin W Gibbs, Heidi L Erickson, Jay S Steingrub, Howard A Smithline, Michelle N Gong, Michael S Aboodi, Matthew C Exline, Daniel J Henning, Jennifer G Wilson, Akram Khan, Nida Qadir, Samuel M Brown, Ithan D Peltan, Todd W Rice, David N Hager, Adit A Ginde, William B Stubblefield, Manish M Patel, Wesley H Self, Leora R Feldstein.
Abstract
Prolonged symptom duration and disability are common in adults hospitalized with severe coronavirus disease 2019 (COVID-19). Characterizing return to baseline health among outpatients with milder COVID-19 illness is important for understanding the full spectrum of COVID-19-associated illness and tailoring public health messaging, interventions, and policy. During April 15-June 25, 2020, telephone interviews were conducted with a random sample of adults aged ≥18 years who had a first positive reverse transcription-polymerase chain reaction (RT-PCR) test for SARS-CoV-2, the virus that causes COVID-19, at an outpatient visit at one of 14 U.S. academic health care systems in 13 states. Interviews were conducted 14-21 days after the test date. Respondents were asked about demographic characteristics, baseline chronic medical conditions, symptoms present at the time of testing, whether those symptoms had resolved by the interview date, and whether they had returned to their usual state of health at the time of interview. Among 292 respondents, 94% (274) reported experiencing one or more symptoms at the time of testing; 35% of these symptomatic respondents reported not having returned to their usual state of health by the date of the interview (median = 16 days from testing date), including 26% among those aged 18-34 years, 32% among those aged 35-49 years, and 47% among those aged ≥50 years. Among respondents reporting cough, fatigue, or shortness of breath at the time of testing, 43%, 35%, and 29%, respectively, continued to experience these symptoms at the time of the interview. These findings indicate that COVID-19 can result in prolonged illness even among persons with milder outpatient illness, including young adults. Effective public health messaging targeting these groups is warranted. Preventative measures, including social distancing, frequent handwashing, and the consistent and correct use of face coverings in public, should be strongly encouraged to slow the spread of SARS-CoV-2.Entities:
Mesh:
Year: 2020 PMID: 32730238 PMCID: PMC7392393 DOI: 10.15585/mmwr.mm6930e1
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Characteristics of symptomatic outpatients with SARS-CoV-2 real-time reverse transcription–polymerase chain reaction (RT-PCR)—positive test results (N = 270)* who reported returning to usual state of health or not returning to usual state of health at an interview conducted 14–21 days after testing — 14 academic health care systems, United States, March–June 2020
| Characteristic | Total | Returned to usual health, no. (row %) | P-value§ | |
|---|---|---|---|---|
| Yes (n = 175) | No (n = 95) | |||
|
| 0.14 | |||
| Women |
| 85 (61) | 55 (39) | |
| Men |
| 90 (69) | 40 (31) | |
|
| 0.010 | |||
| 18–34 |
| 63 (74) | 22 (26) | |
| 35–49 |
| 65 (68) | 31 (32) | |
| ≥50 |
| 47 (53) | 42 (47) | |
|
| 0.29 | |||
| White, non-Hispanic |
| 58 (62) | 36 (38) | |
| Black, non-Hispanic |
| 26 (57) | 20 (43) | |
| Other race, non-Hispanic |
| 24 (75) | 8 (25) | |
| Hispanic |
| 67 (68) | 31 (32) | |
|
| 0.69 | |||
| No |
| 31 (67) | 15 (33) | |
| Yes |
| 135 (64) | 75 (36) | |
|
| 0.003 | |||
| 0 |
| 87 (71) | 36 (29) | |
| 1 |
| 41 (72) | 16 (28) | |
| 2 |
| 21 (54) | 18 (46) | |
| ≥3 |
| 19 (43) | 25 (57) | |
|
| ||||
| Hypertension |
| 33 (52) | 31 (48) | 0.018 |
| Obesity (body mass index >30 kg/m2) |
| 23 (45) | 28 (55) | 0.002 |
| Psychiatric condition |
| 23 (47) | 26 (53) | 0.007 |
| Asthma |
| 23 (64) | 13 (36) | 0.99 |
| Diabetes |
| 16 (57) | 12 (43) | 0.43 |
| Immunosuppressive condition |
| 6 (40) | 9 (60) | 0.047 |
| Autoimmune condition |
| 7 (54) | 6 (46) | 0.44 |
| Blood disorder |
| 4 (50) | 4 (50) | 0.47 |
| Chronic kidney disease |
| 3 (43) | 4 (57) | 0.26 |
| Chronic obstructive pulmonary disease |
| 4 (57) | 3 (43) | 0.71 |
| Liver disease |
| 4 (67) | 2 (33) | 1.00 |
| Neurologic condition |
| 3 (50) | 3 (50) | 0.48 |
| Coronary artery disease |
| 3 (75) | 1 (25) | 1.00 |
| Congestive heart failure |
| 2 (100) | 0 (0) | 0.54 |
* 294 patients responded to an interview 2–3 weeks after testing, did not report a previous positive SARS-CoV-2 test before the reference test, and answered questions about symptoms. Of these, 276 (94%) reported one or more symptoms at the time of SARS-CoV-2 RT-PCR testing, with 272 (99%) reporting whether they had returned to their usual state of health by the time of the interview. Two additional patients excluded who were called at 7 days, with 270 included here.
† Patients were randomly sampled from fourteen academic healthcare systems in 13 states (University of Washington [Washington], Oregon Health and Sciences University [Oregon], University of California Los Angeles and Stanford University [California], Hennepin County Medical Center [Minnesota], Vanderbilt University [Tennessee], Ohio State University [Ohio], Wake Forest University [North Carolina], Montefiore Medical Center [New York], Beth Israel Deaconess Medical Center and Baystate Medical Center [Massachusetts], Intermountain Healthcare [Utah/Idaho], University of Colorado Hospital [Colorado], and Johns Hopkins University [Maryland]).
§ Respondents who reported returning to usual health and respondents who reported not returning to usual health were compared using the chi-square test or Fisher's exact test.
¶ Excluding seven (3%) patients who did not answer questions about chronic underlying medical conditions; for those who answered questions about underlying conditions, some respondents were missing data on obesity (two), neurologic conditions (one), and psychiatric conditions (one).
Characteristics associated with not returning to usual health among symptomatic outpatients with SARS-CoV-2 real-time reverse transcription–polymerase chain reaction (RT-PCR)–positive test results (N = 270)* reported at an interview conducted 14–21 days after testing — 14 academic health care systems, United States, March–June 2020
| Characteristic | Odds of not returning to “usual health” at 14–21 days after testing | |
|---|---|---|
| Unadjusted odds ratio (95% CI)§ | Adjusted odds ratio (95% CI)§,¶ | |
|
| ||
| 18–34 | Referent | Referent |
| 35–49 | 1.40 (0.73–2.67) | 1.38 (0.71–2.69) |
| ≥50 | 2.64 (1.39–5.00) | 2.29 (1.14–4.58) |
|
| ||
| Women | Referent | Referent |
| Men | 0.68 (0.41–1.13) | 0.80 (0.46–1.38) |
|
| ||
| White, non-Hispanic | Referent | Referent |
| Black, non-Hispanic | 1.23 (0.60–2.53) | 1.13 (0.53–2.45) |
| Other, non-Hispanic | 0.53 (0.21–1.31) | 0.63 (0.24–1.61) |
| Hispanic | 0.74 (0.40–1.34) | 0.83 (0.44–1.58) |
|
| ||
| 0 | Referent | Referent |
| 1 | 0.94 (0.47–1.89) | 0.74 (0.35–1.55) |
| 2 | 2.09 (1.00–4.38) | 1.50 (0.68–3.33) |
| ≥3 | 3.19 (1.56–6.50) | 2.29 (1.07–4.90) |
|
| ||
| Hypertension | 1.98 (1.12–3.52) | 1.30 (0.67–2.51) |
| Obesity (BMI >30 kg/m2) | 2.65 (1.42–4.95) | 2.31 (1.21–4.42) |
| Psychiatric condition | 2.42 (1.29–4.56) | 2.32 (1.17–4.58) |
| Asthma | 1.00 (0.48–2.08) | 1.02 (0.47–2.20) |
| Diabetes | 1.38 (0.62–3.05) | 1.06 (0.46–2.44) |
| Immunosuppressive condition | 2.84 (0.98–8.26) | 2.33 (0.77–7.04) |
| Autoimmune condition | 1.55 (0.51–4.76) | 1.05 (0.32–3.46) |
| Blood disorder | 1.82 (0.45–7.45) | 1.43 (0.33–6.24) |
| Chronic kidney disease | 2.42 (0.53–11.05) | 2.36 (0.48–11.51) |
| Chronic obstructive pulmonary disease | 1.34 (0.29–6.12) | 0.70 (0.14–3.48) |
| Liver disease | 0.88 (0.16–4.90) | 0.72 (0.12–4.25) |
| Neurologic condition | 1.78 (0.35–9.01) | 1.23 (0.23–6.62) |
| Coronary artery disease | 0.58 (0.06–5.70) | 0.48 (0.05–4.92) |
| Congestive heart failure | — | — |
Abbreviations: BMI = body mass index; CI = confidence interval.
* 294 patients responded to 14–21-day interview, did not report a previous positive SARS-CoV-2 test before the reference test, and answered questions about symptoms; 276 (94%) of these reported one or more symptoms at the time of SARS-CoV-2 RT-PCR testing, with 272 (99%) reporting whether they had returned to their usual state of health by the time of the interview. Two additional patients who were called at 7 days were excluded, with 270 included here.
† Patients were randomly sampled from academic healthcare systems in 13 states (University of Washington [Washington], Oregon Health and Sciences University [Oregon], University of California Los Angeles and Stanford University [California], Hennepin County Medical Center [Minnesota], Vanderbilt University [Tennessee], Ohio State University [Ohio], Wake Forest University [North Carolina], Montefiore Medical Center [New York], Beth Israel Deaconess Medical Center and Baystate Medical Center [Massachusetts], Intermountain Healthcare [Utah/Idaho], University of Colorado Hospital [Colorado], and Johns Hopkins University [Maryland]).
§ For this analysis, generalized estimation equation (GEE) models with exchangeable correlation structure were used to estimate the association between characteristics and the odds of not returning to usual health by the date of the 14–21-day interview. GEE models were used to account for clustering of cases by site. 95% CIs including 1.00 are not considered statistically significant.
¶ In adjusted GEE models for age, sex, race/ethnicity, and number of chronic medical conditions, the other variables were used to adjust for potential confounders. Models for individual conditions (e.g., hypertension) were adjusted for age, sex, and race/ethnicity.
** Medical conditions are not exclusive and individual patients could have more than one chronic medical condition.
FIGURESelf-reported symptoms at the time of positive SARS-CoV-2 reverse transcription–polymerase chain reaction (RT-PCR) testing results and unresolved symptoms 14–21 days later among outpatients (N = 274)* — 14 academic health care systems, United States, March–June 2020
* 294 patients responded to 14–21-day interview, did not report a previous positive SARS-CoV-2 test before the reference test, and answered questions about symptoms; 276 (94%) of these reported one or more symptoms at the time of SARS-CoV-2 RT-PCR testing; those who were interviewed at 7 days were excluded, with 274 included here.
† Patients were randomly sampled from 14 academic health care systems in 13 states (University of Washington [Washington], Oregon Health and Sciences University [Oregon], University of California Los Angeles and Stanford University [California], Hennepin County Medical Center [Minnesota], Vanderbilt University [Tennessee], Ohio State University [Ohio], Wake Forest University [North Carolina], Montefiore Medical Center [New York], Beth Israel Deaconess Medical Center and Baystate Medical Center [Massachusetts], Intermountain Healthcare [Utah/Idaho], University of Colorado Hospital [Colorado], and Johns Hopkins University [Maryland]).